Clinical pharmacokinetics of nifedipine. Implications for the care of the elderly
- PMID: 9413704
- DOI: 10.2165/00002512-199711060-00006
Clinical pharmacokinetics of nifedipine. Implications for the care of the elderly
Abstract
Nifedipine, the prototype for the dihydropyridine class of calcium antagonists, has been available for 20 years and its efficacy as a vasodilator and an antihypertensive agent is well recognised. The development of the so-called nifedipine gastrointestinal therapeutic system (GITS), which allows once-daily administration, has modified and improved the overall therapeutic profile of nifedipine to such a significant extent that it might almost be considered a new drug entity. The nifedipine GITS is associated with distinct improvements in terms of patient compliance and convenience, and a reduced incidence of adverse effects. With regard to the care of the elderly, this 'new' drug offers the prospect of a well tolerated and effective treatment without major cost implications.
Similar articles
-
The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties.Clin Pharmacokinet. 1996 Jan;30(1):28-51. doi: 10.2165/00003088-199630010-00003. Clin Pharmacokinet. 1996. PMID: 8846626 Review.
-
Modified-release nifedipine: a review of the use of modified-release formulations in the treatment of hypertension and angina pectoris.Drugs. 2006;66(4):497-528. doi: 10.2165/00003495-200666040-00007. Drugs. 2006. PMID: 16597165 Review.
-
Clinical pharmacokinetics of vasodilators. Part I.Clin Pharmacokinet. 1998 Jun;34(6):457-82. doi: 10.2165/00003088-199834060-00003. Clin Pharmacokinet. 1998. PMID: 9646008 Review.
-
Once daily nifedipine: the formulation dictates the pharmacokinetic characteristics and the therapeutic responses.Int J Clin Pharmacol Ther. 2012 Mar;50(3):202-17. doi: 10.5414/cp201603. Int J Clin Pharmacol Ther. 2012. PMID: 22373833
-
Pharmacokinetics and safety of nifedipine GITS/candesartan fixed-dose combination in subjects with hepatic impairment .Int J Clin Pharmacol Ther. 2017 Mar;55(3):246-255. doi: 10.5414/CP202700. Int J Clin Pharmacol Ther. 2017. PMID: 28025965 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical